当前位置:首页 - 行情中心 - 海辰药业(300584) - 财务分析 - 利润表

海辰药业

(300584)

  

流通市值:53.05亿  总市值:77.53亿
流通股本:8211.07万   总股本:1.20亿

利润表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、营业总收入308,572,571.42142,649,339.94504,360,394.59360,497,824.16
  营业收入308,572,571.42142,649,339.94504,360,394.59360,497,824.16
二、营业总成本268,183,609.26124,158,918.05454,644,738.59324,027,907.82
  营业成本43,561,139.3719,842,260.4984,980,990.8260,911,488.02
  税金及附加6,608,200.113,185,104.1110,641,872.717,940,032.54
  销售费用128,610,941.1856,390,082.47201,766,882.46150,433,501.51
  管理费用69,016,888.3138,657,009.14107,887,139.5563,620,585.66
  研发费用16,902,144.444,331,960.1440,275,869.5134,268,297.38
  财务费用3,484,295.851,752,501.79,091,983.546,854,002.71
  其中:利息费用3,525,526.131,774,305.648,983,022.826,820,431.18
  其中:利息收入37,528.321,383.36113,603.4894,120.82
三、其他经营收益
  加:公允价值变动收益---1,705.87
  加:投资收益-1,225,456.46-7,469.683,318.69-120,412.6
  资产处置收益482,279.37---52,414.95
  资产减值损失(新)-9,351,690.62-3,931,326.87-9,884,051.74-6,808,591.63
  信用减值损失(新)716,669.921,437,594.09834,439.481,189,426.54
  其他收益664,082.56528,271.121,138,876.31681,467.03
四、营业利润31,674,846.9316,517,490.5541,808,238.7431,361,096.6
  加:营业外收入31,311.2919,301.18570,272.4524,264.04
  减:营业外支出375,787.15184,971.081,348,204.261,175,224.66
五、利润总额31,330,371.0716,351,820.6541,030,306.9330,210,135.98
  减:所得税费用2,451,894.321,388,950.76867,335.682,093,329.35
六、净利润28,878,476.7514,962,869.8940,162,971.2528,116,806.63
(一)按经营持续性分类
  持续经营净利润28,878,476.7514,962,869.8940,162,971.2528,116,806.63
(二)按所有权归属分类
  归属于母公司股东的净利润29,157,742.4115,036,959.7640,217,910.8828,116,806.63
  少数股东损益-279,265.66-74,089.87-54,939.63-
  扣除非经常损益后的净利润28,851,005.7315,001,968.1440,617,505.2229,066,322.35
七、每股收益
  (一)基本每股收益0.240.130.340.23
  (二)稀释每股收益0.240.130.340.23
九、综合收益总额28,878,476.7514,962,869.8940,162,971.2528,116,806.63
  归属于母公司股东的综合收益总额29,157,742.4115,036,959.7640,217,910.8828,116,806.63
  归属于少数股东的综合收益总额-279,265.66-74,089.87-54,939.63-
公告日期2025-08-232025-04-212025-04-212024-10-26
审计意见(境内)标准无保留意见
TOP↑